Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

OBJECTIVE: To investigate the cost-effectiveness of ramucirumab plus erlotinib compared with placebo plus erlotinib in the first-line setting for patients with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) from the Chinese healthcare system perspective. DESIGN: A Markov model consistin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692814/
https://www.ncbi.nlm.nih.gov/pubmed/33243806
http://dx.doi.org/10.1136/bmjopen-2020-040691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692814/
https://www.ncbi.nlm.nih.gov/pubmed/33243806
http://dx.doi.org/10.1136/bmjopen-2020-040691

Ejemplares similares